A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly distributed biologically active micellizing amphiphilic molecule, the size of these pores ranging from about 0.5 to about 100 nanometers. The material is characterized in that when exposed to phosphate-buffered saline (PBS), the controlled release of the active amphiphilic molecule is predominantly diffusion-driven over time.

The invention relates to a bioactive bone repair substrate comprising granules obtainable by or obtained from a set solid state mixture of a calcium phosphate based bone repair matrix and a bioactive material, preferably granules having an average diameter between 25 and 10,000 μm.

Provided herein are compositions for bone formation, comprising a scaffold of hydroxyapatite (HA) and tricalcium phosphate (TCP) in a ratio of from 0/100 to 15/85, collagen, and bioactive glass, wherein the bioactive glass is uniformly dispersed in both interior and surface portions of the scaffold, and wherein the composition is sterilized and packaged.

A method for producing granules of a uniform size includes preparing an organic member solution, uniformly dispersing an inorganic member in the organic member solution at a weight ratio of 1 to 10 based on an organic member to form an organic-inorganic composite solution, spraying the organic-inorganic composite solution in an electrostatic charge manner, and polymerizing the sprayed organic-inorganic composite solution to form a hydrogel phase. The granules having a uniform size may be mass-produced in a short time and may be produced at a high yield. The method may be applied to a variety of fields, such as a pharmaceutical field, a medical field, a cosmetics field, and a food field and may replace a conventional spray drying method.

The present invention relates to a glass ceramic composition comprising SiO.sub.2, Ca(OH).sub.2, CaF.sub.2, B.sub.2O.sub.3, MgO, and hydroxyapatite; a bioactive crystallized glass ceramic comprising each of CaSiO.sub.3, Ca.sub.10(PO.sub.4).sub.6(OH).sub.2, and CaMgSi.sub.2O.sub.6 in an amount of 20% to 60% by weight; an implant for early osseointegration comprising the glass ceramic; and a method for manufacturing the implant.

Porous ceramics that meet the demand for bone substitute materials and the like are provided. Solution is provided by porous ceramics and a method for producing the porous ceramics, which are ceramics having pores, the pores including open pores and closed pores, the open pores including a plurality of large-diameter open pores having a pore size within a range of 20 to 600 μm and a plurality of micro-diameter open pores having a pore size within a range of 1.0 μm or smaller, wherein the large-diameter open pores are distributed substantially uniformly all over the ceramics.

To provide a bioimplant capable of controlling a rate of an antibacterial agent and an antibiotic to be eluted from the coating film. An evanescent coating film made of a calcium phosphate-based material having crystallinity of 10% to 90% is formed at a predetermined area of the bioimplant and an antibacterial agent or an antibiotic is contained in the coating film to suppress adhesion of bacteria.

A method of preparing an inorganic binder for medical use according to an embodiment of the present disclosure includes preparing a starting material using a-TCP powder and phosphate powder each of which has a predetermined particle size, producing a paste having a predetermined viscosity that is suitable for formation of a molded article having a predetermined shape by homogeneously mixing the starting material, adding water or saline to the homogeneously mixed starting material, and kneading the resulting mixture, subjecting the molded article to hydration reaction, and washing and drying the molded article having undergone the hydration reaction to obtain an inorganic binder containing OCP and HA crystal phases.

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.